⌘K

Login Start Free

Home/Filings/4/0001127602-23-002753

4//SEC Filing

Eisele Jeffrey 4

Accession 0001127602-23-002753

CIK 0001492422other

View on SEC.gov Company Profile

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 4:51 PM ET

Size

4.4 KB

Accession

0001127602-23-002753

Insider Transaction Report

Form 4

Period: 2023-01-30

Apellis Pharmaceuticals, Inc.APLS

Chief Development Officer

Transactions

Sale
Common Stock
2023-01-30$52.76/sh−883$46,587→ 46,468 total

Footnotes (1)

[F1]Sale originated from established 10b5-1 trading plan.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1

filerCIK 0001827326

Filing Metadata

Form type: 4
Filed: Jan 30, 7:00 PM ET
Accepted: Jan 31, 4:51 PM ET
Size: 4.4 KB

View on SEC.gov